《中外医学研究》第18卷 第27期（总第467期）2020年9月 临床与实践 Linchuangyushijian
- 23 -
Chine and Foreign Medical Rearch Vol.18, No.27 September , 2020
影响因素分析[J].中华妇产科杂志，2016，51（7）：535-537.[3]中华医学会妇产科学分会产科学组.妊娠期肝内胆汁淤积症诊疗指南（2015）[J].中华妇产科杂志，2015，50（7）：481-485.
[4]肖凤莲，郑英如.妊娠期肝内胆汁淤积症总胆汁酸水平及终止妊娠时间与围产儿结局的关系[J].第三军医大学学报，2018，40（11）：1028-1032.
滚圈圈[5] Lo J O，Shaffer B L，Allen A J，et al.Intrahepatic cholestasis of pregnancy and timing of delivery[J].J Matern Fetal Neonatal Med，2015，28（18）：2254-2258.
[6]热依汗古丽·买买提，刘海燕，韩文晖，等.妊娠期肝内胆汁淤积症对早产发生率的影响[J].中华流行病学杂志，2017，38（10）：1415-1418.
[7]韦懿芸，庞丽红.妊娠期肝内胆汁淤积症90例临床分析[J].广东医学，2017，38（z1）：167-169.
[8]李阳芳，程群仙，李航，等.妊娠期肝内胆汁淤积症孕妇总胆汁酸水平与妊娠不良结局研究[J].肝脏，2019，24（7）：817-818.
网络追踪[9]李亚男，韦娟冰.早发及晚发型妊娠期肝内胆汁淤积症患者围生儿结局观察[J].肝脏，2019，24（6）：635-637.亚马逊河有多长
[10] Estiú M C，Frailuna M A，Otero C，et al.Relationship between early
ont vere intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid[J].PLoS One，2017，12（4）：e0176504.[11] Lin J，Gu W，Hou Y.Diagnosis and prognosis of early-ont intrahepatic
cholestasis of pregnancy：a prospective study[J].J Matern Fetal Neonatal Med，2019，32（6）：997-1003.
[12]卢春冬，林安平，常青，等.适当延长妊娠期肝内胆汁淤积症孕妇
2022年春节孕周对围生儿结局的影响[J].第三军医大学学报，2015，37（14）：1455-1459.
（收稿日期：2020-08-03） （本文编辑：桑茹南）
①厦门大学附属福州第二医院 福建 福州 350007
奥曲肽联合苯扎贝特、低分子肝素钙治疗高脂血症
胰腺炎的临床效果
叶思婷①
爱护草坪的宣传语
【摘要】 目的：探讨奥曲肽联合苯扎贝特、低分子肝素钙治疗高脂血症胰腺炎的临床效果及对炎症因子水平的影响。方法：选取2017年4月- 2019年5月笔者所在医院收治的高脂血症胰腺炎患者80例。按随机数字表法将其均分为观察组和对照组。对照组采取苯扎贝特及低分子肝素钙治疗，观察组在对照组的基础上联合奥曲肽治疗。对比两组临床疗效；记录两组厌食、腹部疼痛及恶心呕吐等不良反应发生率；对比两组首次通气时间、胃肠减压时间及腹痛缓解时间等临床症状指标；对比两组CRP、IL-6及IL-33等炎症因子水平。结果：观察组患者治疗总有效率（97.50%）显著高于对照组患者的70.00%（P <0.05）；观察患者不良反应总发生率（5.00%）显著低于对照组患者的25.00%（P <0.05）；观察组患者首次通气时间、胃肠减压时间及腹痛缓解时间均早于对照组患者（P <0.05）；两组患者CRP、IL-6及IL-33水平较治疗前均有所降低，但治疗后观察组患者各炎症因子水平均显著低于对照组（P <0.05）。结论：奥曲肽联合苯扎贝特、低分子肝素钙治疗高脂血症胰腺炎的临床疗效确切，能有效缓解患者临床症状，降低患者体内IL-33等炎性因子的表法水平，进而降低患者不适感。同
石港中学
时减少不良反应发生情况，具有较高的药物安全性，具有广阔的应用前景，值得临床运用与推广。
七个阿姨来摘果【关键词】 奥曲肽 苯扎贝特 低分子肝素钙 高脂血胰腺炎 doi：10.ki.cfmr.2020.27.009
文献标识码 B
文章编号 1674-6805（2020）27-0023-03
Clinical Effect of Octreotide Combined with Benzabate and Low Molecular Heparin Calcium on Hyperlipidemic Pancreatitis/YE Siting. //Chine and Foreign Medical Rearch, 2020, 18(27): 23-25
[Abstract] Objective: To investigate the clinical effect of Octreotide combined with benzabate and Low Molecular Heparin Calcium in the treatment of hyperlipidemic pancreatitis and its influence on inflammatory factors levels. Method: A total of 80 patients with hyperlipidemia pancreatitis admitted to our hospital from April 2017 to May 2019 were lected. They were divided into obrvation group and control group according to random number table method. The control group was treated with Benzabate and Low molecular weight heparin calcium, and the obrvation group was treated with Octreotide on the basis of the control group. The clinical efficacy of the two groups was compared. T
奥斯卡最佳导演奖
he incidence of anorexia, abdominal pain, naua and vomiting was recorded. The first ventilation time, gastrointestinal decompression time and abdominal pain relief time were compared between the two groups. The levels of inflammatory factors such as CRP, IL-6 and IL-33 were compared between the two groups. Result: The total effective rate (97.50%) in the obrvation group was significantly higher than 70.00% in the control group (P <0.05). The total incidence of adver reactions in the obrved patients (5.00%) was significantly lower than 25.00% in the control group (P <0.05). The first ventilation time, gastrointestinal decompression time and abdominal pain relief time in the obrvation group were all lower than tho in the control group (P <0.05). The levels of CRP, IL-6 and IL-33 in both groups were lower than tho before treatment, but the levels of all inflammatory factors in the obrvation group were significantly lower than tho in the control group after treatment (P <0.05). Conclusion: Octreotide combined with Benzodiazepine and Low Molecular
